	销售和管理费用		日
argenx SE	USD 355M	74.62M	2026-03
AstraZeneca	USD 5.06B	455M	2026-03
Biogen	USD 554.3M	128.2M	2026-03
Genmab	DKK 208M	60M	2025-12
Gilead Sciences	USD 1.45B	326M	2026-03
GlaxoSmithKline	GBP 2.12B	558M	2026-03
GRIFOLS	EUR 281M	5.7M	2026-03
Hikma Pharmaceutical	USD 288M	149M	2025-12
Incyte	USD 328.1M	62.31M	2026-03
Merck	EUR 1.52B	80M	2026-03
Neurocrine Biosciences	USD 318.5M	16.7M	2026-03
Novartis	USD 3.14B	296M	2026-03
Roche Holding	CHF 7.28B	3.99B	2025-12
Sanofi	EUR 2.33B	419M	2026-03
UCB	EUR 1.47B	193M	2025-12
Vertex Pharmaceuticals	USD 493.7M	6.7M	2026-03